Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Friday 20 February, 2009


UCB announces top-line outcomes for proof-of-co...

Lacosamide in migraine prophylaxis and rotigotine in fibromyalgia
syndrome did not achieve statistical significance for their primary

Brussels, Belgium, 20 February 2009 at 6:00 PM (CET) - press release,
regulated information - UCB announced today top-line results from two
proof-of-concept Phase IIa clinical trials to assess the efficacy and
safety of lacosamide in migraine prophylaxis, and the efficacy and
safety of rotigotine in fibromyalgia syndrome. These trials were
designed to determine whether there is justification for further
clinical development of lacosamide and rotigotine in these
indications.  The respective studies did not achieve statistical
significance for their primary endpoints. UCB will evaluate
development plans once full analyses are available.

Phase IIa study: lacosamide in migraine prophylaxis
The multicentre, randomized, double-blind, placebo-controlled trial
was designed to evaluate the efficacy of lacosamide (100 mg/day and
300 mg/day) compared to placebo in reducing the frequency of
migraine. The primary efficacy variable was the mean reduction of
migraine rates during the 14-week maintenance period compared to the
average frequency during the 4-week baseline period. Patients in this
trial (218) had a history of episodic migraine with or without aura
for at least 1 year and a well-documented three month retrospective
history of migraines prior to enrolment. The trial did not meet its
primary endpoint. However, a reduction in headache frequency was
consistently observed in all treatment groups.

Phase IIa study: rotigotine in fibromyalgia syndrome
The multicentre, randomized, double-blind, placebo-controlled trial
was designed to investigate the efficacy and safety of rotigotine (4
mg/24 h and 8 mg/24 h) compared to placebo in adult patients (240)
with signs and symptoms of fibromyalgia syndrome. The primary
efficacy variable was the reduction in pain for patients taking
rotigotine as measured by the average Likert pain score at baseline
to the last two weeks of the 13 week treatment period. The study
results did not achieve statistical significance for its primary
endpoint. Only primary efficacy and safety data have been reviewed at
this time.

About UCB
UCB, Brussels, Belgium ( is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing more than 10 000 people in
over 40 countries, UCB aims to achieve revenues of at least EUR3.3
billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

For further information
Antje Witte, Corporate Communications & Investor Relations, UCB
T +32.2.559.9414,

Richard Simpson, Investor Relations, UCB
T +32 2 559 94 94,

About Migraine
Migraine is a common, disabling primary headache disorder. It
typically affects one side of the head and may be pulsating, of
moderate to severe intensity, and aggravated by routine activity.
Migraine headache can last up to two to three days and is commonly
accompanied by nausea and vomiting, and/or intolerance to normal
levels of light and sound. Migraine is two to three times more common
in women than men.

About Fibromyalgia
Fibromyalgia is an idiopathic, chronic, pain syndrome defined by
widespread musculoskeletal pain and generalized tender points. Other
common symptoms include sleep disturbances, fatigue, headache,
morning stiffness and anxiety. Fibromyalgia is usually considered a
disorder of women aged 20 to 50 years; however, it has also been
observed in men, children, adolescents and older persons.
Fibromyalgia is more common in relatives of people with fibromyalgia,
suggesting the contribution of genetic factors.

Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

For the pdf version of this press release, please click on the link

This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.